

1 **Cerebral perivascular spaces as predictors of dementia risk and accelerated brain**
2 **atrophy**

3 Giuseppe Barisano, M.D., Ph.D.^{1*}, Michael Iv, M.D.², on behalf of the Alzheimer's
4 Disease Neuroimaging Initiative, Jeiran Choupan, Ph.D.³, and Melanie Hayden-
5 Gephart, M.D.¹

6

7 1. Department of Neurosurgery, Stanford University, Stanford, CA, USA

8 2. Department of Radiology, Stanford University, Stanford, CA, USA

9 3. Laboratory of Neuro Imaging, University of Southern California, Los Angeles, CA, USA

10

11 *Corresponding author.

12 Department of Neurosurgery, Stanford University,

13 1201 Welch Rd., Stanford, CA, 94305

14 E-mail address: barisano@stanford.edu (Giuseppe Barisano)

15

16 Abstract

17 Cerebral small vessel disease, an important risk factor for dementia, lacks robust, *in*
18 *vivo* measurement methods. Perivascular spaces (PVS) on brain MRI are surrogates for
19 small parenchymal blood vessels and their perivascular compartment, and may relate to
20 brain health. We developed a novel, robust algorithm to automatically assess PVS
21 count and size on MRI, and investigated their relationship with dementia risk and brain
22 atrophy. We analyzed 46,478 clinical measurements of cognitive functioning and 20,845
23 brain MRI scans from 10,004 participants (71.1±9.7 years-old, 56.6% women). Fewer
24 PVS and larger PVS diameter at baseline were associated with higher dementia risk
25 and accelerated brain atrophy. Longitudinal trajectories of PVS markers were
26 significantly different in non-demented individuals who converted to dementia compared
27 with non-converters. In simulated placebo-controlled trials for treatments targeting
28 cognitive decline, screening out participants less likely to develop dementia based on
29 our PVS markers enhanced the power of the trial. These novel radiographic
30 cerebrovascular markers may improve risk-stratification of individuals, potentially
31 reducing cost and increasing throughput of clinical trials to combat dementia.

32

33 Introduction

34 Cerebral small vessel disease, the most common vascular disease affecting the blood
35 vessels within the brain parenchyma, is considered a significant and potentially reversible
36 contributor to cognitive decline and dementia.^{1,2} *Ex vivo* studies have shown an
37 independent association of cerebral small vessel neuropathology with cognitive function
38 and many subtypes of dementia.^{3–7} Given the known association with dementia risk, it is
39 important to identify robust radiographic markers of the cerebral small vessels, to properly
40 risk-stratify patients, monitor disease, and assess the impact of treatment.

41 *In vivo* evaluation of cerebral small vessel disease relies on magnetic resonance imaging
42 (MRI) and includes different signs of brain parenchymal damage (e.g., white matter
43 lesions, lacunes, subcortical infarcts, cerebral microbleeds, and enlargement of
44 perivascular spaces).⁸ Yet these MRI findings may not be detectable in the healthy
45 population, lack quantitative granularity, require specific MRI sequences, or are labor
46 intensive to process.^{1,2} Using the perivascular space as detected on MRI to non-
47 invasively evaluate cerebral small vessel health requires only an unenhanced 3-
48 dimensional T1-weighted images,⁹ a nearly universal brain MRI sequence. Current
49 techniques of perivascular space estimation^{10–15} though suffer from user-dependency,
50 and weak or unknown robustness and inter-scanner reproducibility^{1,9,16–18}. These
51 limitations prevent generalized, widespread use in the hospital, clinical trials, and multi-
52 center longitudinal studies. New, robust tools, therefore, are needed to investigate the
53 temporality and nonspurious dose-response relationship between perivascular spaces
54 (as a surrogate of cerebral small vessels) and dementia.

55 To meet this critical need, we developed and validated a novel, fully automated approach
56 to robustly assess the perivascular spaces in the white matter (WM-PVS) and basal
57 ganglia (BG-PVS) requiring as input only unenhanced 3-D T1-weighted images. Despite
58 some possible limitations in PVS visual detection compared with T2-weighted images,⁸
59 3-D T1-weighted images are more commonly included in brain MRI protocols.¹⁹ We
60 employed our novel method to investigate the association of baseline PVS with the risk
61 of developing dementia and the brain atrophy trajectory. We focused on two properties:
62 the number of perivascular spaces on T1-weighted image (hereinafter referred to as PVS
63 count), and PVS mean diameter. We also included in our analyses the (log-transformed)
64 volume of white matter lesions in the periventricular area (P-WML) and deep white matter
65 (D-WML), since they can similarly be measured on T1-weighted images and are
66 considered closely related to PVS.⁸

67 Given that the inclusion of individuals with low risk of cognitive decline reduces the power
68 of clinical trials evaluating a treatment effect on cognitive impairment,²⁰ we evaluated the
69 potential benefit of our novel PVS markers as a screening tool to enrich for individuals
70 likely to develop dementia and compared their performance with that of standard WML
71 and atrophy markers assessed on T1-weighted images.

72 Results

73 Technical validation of PVS and WML markers

74 The spatial overlap between the PVS masks obtained with our novel fully automated
75 approach and those obtained with a previously validated semi-automated technique^{12,13,17}

76 was very high (average Dice similarity coefficient: 0.95 ± 0.0001) and the numbers of PVS
77 voxels identified with the two methods were strongly correlated (Spearman's $\rho=0.94$,
78 $P<0.001$, Fig. S3A). Consistently, PVS measured with our method also showed a strong
79 positive association with age, male sex, and body mass index in the Human Connectome
80 Project dataset (Fig. S3B-D), replicating results previously published with the validated
81 semi-automated techniques.²¹⁻²³ These data support the reliability and accuracy of our
82 PVS masks. While previous methods are user-dependent (i.e., the user needs to identify
83 a threshold for each type of T1-weighted image) and lack inter-scanner reproducibility of
84 PVS markers^{1,9,16-18} (Fig. S1A-B), our technique is able to provide measurements of PVS
85 count and diameter in a fully automated and robust way. Indeed, both metrics showed
86 excellent intraclass correlation coefficients (≥ 0.9 for WM-PVS and ≥ 0.8 for BG-PVS) for
87 inter-scanner reproducibility, inter-field-strength reproducibility, and test-retest
88 repeatability (Figure S4). We also observed a strong correlation between the numbers of
89 PVS voxels independently identified by our algorithm on the T1- and T2-weighted images
90 (Spearman's $\rho=0.98$, $P<0.001$, Fig. S5A), with an average of $87.3 \pm 5.7\%$ of PVS voxels
91 detected on T1-weighted images that overlapped with PVS voxels on T2-weighted
92 images. Overall, these data show that our method can accurately segment PVS on T1-
93 weighted images and that T1-weighted images are suitable to reliably assess PVS
94 morphological metrics and inter-subject differences. In contrast with previous methods,¹⁰⁻
95 ¹⁵ our new approach for PVS segmentation is fully automated, requires only T1-weighted
96 images, and provides robust metrics across different scanners and protocols (Figure S4).
97 Concerning the segmentation of WML, which we performed with a previously validated
98 technique,²⁴ we confirmed that T1-weighted images, despite considered less sensitive

99 than FLAIR images for the detection of WML,⁸ allow to obtain valid estimates of WML
100 volume, as the number of WML voxels detected on T1-weighted images were strongly
101 correlated with those detected on FLAIR (Spearman's $\rho=0.82$, $P<0.001$, Fig. S5B), and
102 $83.0\pm 0.4\%$ of WML voxels detected on T1-weighted images spatially overlapped with
103 WML voxels detected on FLAIR. The derived measurements of WML volume also
104 showed excellent intraclass correlation coefficients (≥ 0.95 for P-WML, ≥ 0.83 for D-WML)
105 for inter-scanner reproducibility, inter-field-strength reproducibility, and test-retest
106 repeatability (Figure S6).

107 Study population

108 The baseline characteristics of the 10,004 participants stratified by study cohort are
109 reported in Table 1. There were 8867 non-demented subjects and 1137 patients with
110 dementia, including 996 clinically diagnosed with probable or possible Alzheimer's
111 dementia, 51 Lewy body dementia, 38 frontotemporal dementia, 1 vascular dementia,
112 and 51 other or uncertain type of dementia. Accuracy of the PVS masks were visually
113 verified for all the cases in a blinded fashion by an expert physician-scientist according to
114 established criteria.⁸ We also developed an interactive website that allows the readers to
115 visualize our PVS segmentations and independently verify their accuracy:
116 <https://gbarisano.shinyapps.io/pvs-dementia>.

117 In multivariate analyses, all PVS and WML markers were significantly associated with
118 age, sex, body mass index, cognitive scores, and history of hypertension (Table S2).
119 History of diabetes was associated with all PVS markers except BG-PVS diameter;
120 history of cardiovascular disease was associated with BG-PVS diameter. In the subgroup

121 analysis (Table S3), WM-PVS count was not significantly associated with APOE
122 genotype, amyloid or tau status, and BG-PVS count was negatively associated with
123 amyloid status and APOE- $\epsilon 4\epsilon 4$ -carrier status. WM-PVS diameter, P-WML and D-WML
124 volume were associated with positive amyloid and APOE- $\epsilon 4\epsilon 4$ -carrier status. BG-PVS
125 diameter was associated with positive tau and APOE- $\epsilon 4\epsilon 4$ -carrier status.

126 After controlling for study cohort, demographic, and clinical variables, demented patients
127 showed significantly lower WM- and BG-PVS count, higher WM- and BG-PVS diameter,
128 and higher P-WML volume compared with non-demented subjects (estimated marginal
129 means in Table S4). Consistent results for WM-PVS count, BG-PVS count, and P-WML
130 were obtained in sensitivity analyses (Table S5), indicating that their differences are
131 independent of APOE, amyloid, or tau status.

132 PVS markers and risk of dementia

133 Among 7518 non-demented participants with at least 1 follow-up visit (Table S6), 1493
134 individuals developed dementia during a median follow-up of 4.1 years (interquartile
135 range, 2.3-7.1), including 1306 clinically diagnosed with probable or possible Alzheimer's
136 dementia, 43 Lewy body dementia, 29 frontotemporal dementia, 16 vascular dementia,
137 and 99 other or uncertain type of dementia. In the fully adjusted models of the two-stage
138 pooled analysis, risk of dementia was significantly associated with baseline WM-PVS and
139 BG-PVS count and diameter. Each additional 100 WM-PVS and 10 BG-PVS were
140 significantly associated with 20% and 9% decreased dementia risk, respectively, and
141 each additional 0.1-mm increase in WM-PVS and BG-PVS mean diameter were
142 significantly associated with 9% and 20% increased dementia risk, respectively (Fig. 1A-

143 D). P-WML, but not D-WML, was also significantly associated with dementia risk (Fig. 1E-
144 F). The spline analysis with pooled data supported a linear association over the range of
145 the PVS and P-WML markers measured in this population (Fig. 1G-K). Sensitivity
146 analyses showed substantially unchanged results, suggesting that these effects are
147 independent of other potential confounding factors, including the positivity status for
148 amyloid or tau biomarkers (Table S7 and Fig. S7). The association of WM-PVS diameter
149 with dementia risk became not statistically significant after adding amyloid status in the
150 model.

151 PVS markers and brain atrophy

152 Among 3389 non-demented participants with at least 2 MRI scans (Table S8), we
153 investigated the association of PVS and WML markers measured at the baseline MRI
154 with the trajectory of brain atrophy estimated over a total of 14,229 MRI scans (average
155 of 4 scans available per subject) during a median follow-up time of 3.1 years (interquartile
156 range 2.0 to 5.6 years). In the mixed-effect models fully adjusted for demographic, clinical,
157 and MRI-related covariates, the association of PVS and WML markers with the
158 longitudinal trajectory of brain atrophy were statistically significant (Fig. 2A, Table S9).
159 Each additional 100 WM-PVS and 10 BG-PVS identified at the baseline were associated
160 with preservation of additional $709 \pm 100 \text{ mm}^3$ and $187 \pm 33 \text{ mm}^3$ of total grey matter volume
161 every year, respectively. Each 0.1 mm increase in WM-PVS and BG-PVS diameter was
162 associated with loss of additional $382 \pm 84 \text{ mm}^3$ and $576 \pm 137 \text{ mm}^3$ of total grey matter
163 volume every year, respectively. Each logarithmic unit increase in P-WML and D-WML
164 volume was associated with loss of additional $288 \pm 46 \text{ mm}^3$ and $189 \pm 62 \text{ mm}^3$ of total grey
165 matter volume every year, respectively. Similar results were obtained for cortical

166 thickness (Fig. 2B, Tables S9). Most of the effects for the grey matter volume and cortical
167 thickness were observed in the temporal lobes, bilaterally, for all markers (Fig. 2A-B
168 bottom rows, respectively; Tables S10 and S11, respectively). For white matter volume,
169 only WM-PVS count, BG-PVS count and BG-PVS diameter were significantly associated
170 with accelerated atrophy (Fig. 2C, Tables S9). These effects and their spatial patterns
171 remained significant for most markers in all sensitivity analyses, indicating that the link
172 between these markers and accelerated atrophy is independent of other potential
173 confounding factors, including the positivity status for amyloid or tau biomarkers (Figures
174 S8-S10, Table S13). Exceptions included WM-PVS and BG-PVS diameter, which
175 became not significant after adding tau status in the model for grey matter volume (Fig.
176 S8, Table S13), but remained significant for cortical thickness (Fig. S9, Table S13); BG-
177 PVS diameter became not significant after adding amyloid status in the model for white
178 matter volume (Fig. S10, Table S13). Overall, these data showed that fewer WM-PVS
179 and BG-PVS counts were associated with accelerated brain atrophy. This effect was
180 stronger on the grey matter volume and cortical thickness of the temporal lobes,
181 irrespective of amyloid and tau positivity status. Similar associations were found for WM-
182 PVS and BG-PVS diameter, although they were generally less robust when considering
183 amyloid and/or tau status in the model.

184 We further assessed the relationship between the WM-PVS marker measured in a
185 specific lobe and the corresponding atrophy in that lobe. The spatial patterns for regional
186 WM-PVS count (Fig. S11, left column) were consistent with those observed in the main
187 model with global WM-PVS count (Fig. 2). Less consistency was observed for regional
188 WM-PVS diameter (Fig. S11, right column). This suggests a spatial relationship between

189 the atrophy trajectory of a specific brain region and the corresponding WM-PVS count in
190 that region at baseline.

191 Based on previous results from preclinical studies^{25,26}, we hypothesized that one potential
192 mechanism linking PVS with accelerated brain atrophy could be alterations in cerebral
193 blood flow. Indeed, in most of the brain regions we observed a significant correlation of
194 the regional PVS count and diameter with the corresponding regional cerebral blood flow
195 as assessed *in vivo* with arterial spin labeling MRI (Fig. S12). This suggested that the
196 observed effects of PVS on accelerated brain atrophy might have been related to
197 decreased blood flow. However, the relatively low sample size of subjects with cerebral
198 blood flow data available at the baseline (N=224) prevented us from building reliable
199 linear mixed-effects models evaluating the relative contribution of cerebral blood flow and
200 PVS to the brain atrophy trajectory while accounting for the relevant clinical and
201 demographic covariates included in all our models. No significant correlations with
202 cerebral blood flow were found for P-WML and D-WML (Fig. S12).

203 Finally, we estimated the longitudinal trajectory of the PVS and WML markers in non-
204 demented individuals who converted to dementia and compared it with those who did not
205 convert. The WM and BG regions where PVS were measured were spatially-registered
206 and kept consistent across the intra-individual timepoints. This means that, for each
207 subject, PVS were analyzed in the exact same voxels across timepoints. The longitudinal
208 trajectories of PVS count and mean diameter significantly differed between converters
209 and non-converters, both in the white matter and in the basal ganglia: PVS count in
210 converters, who already had lower PVS count compared with non-converters at the
211 baseline MRI (Table S14), further decreased with time. PVS count remained stable in

212 non-converters (Figure 3A and C). On the other hand, WM-PVS and BG-PVS mean
213 diameter (Figure 3B and D, respectively) were stable in converters, who already had
214 significantly higher baseline PVS diameter compared with non-converters (Table S14).
215 WM-PVS and BG-PVS mean diameter decreased in non-converters. Sensitivity analyses
216 showed consistent results (Figure S13), indicating that the different trajectories for these
217 markers in converters versus non-converters were independent of other potential
218 confounding factors such as amyloid and tau status. In WM-PVS markers, the differences
219 between converters and non-converters involved mostly the left hemisphere, especially
220 the frontal and parietal lobes (Figure 3A and B). Significant increases over time in P-WML
221 volume were also found, which were more prominent in converters compared with non-
222 converters (Figure 3E). Overall, these data indicate that the differences in PVS count and
223 diameter measured at the baseline MRI scans of dementia converters versus non-
224 converters followed different longitudinal trajectories: in converters, larger baseline PVS
225 remain enlarged, and lower baseline PVS count continue decreasing.

226

227 PVS markers in simulated clinical trials

228 In 48-month placebo-controlled trials simulated with 40,703 cognitive assessments in
229 7518 non-demented participants, the sample size required to detect a 30% slowing in
230 cognitive decline (assessed with the CDR) with 80% power was lower when selectively
231 screening out participants based on the PVS or the WML markers' tertiles (Table S16):
232 sample size reductions were 13-37% when enrolling participants in the medium- and high-
233 risk tertiles (Figure 4, red bars), and 28-63% when enrolling participants in the high-risk

234 tertile only (Figure 4, blue bars). The performance was comparable to that observed for
235 the atrophy markers cortical thickness and grey matter volume (respectively 53% and
236 37% reductions when including individuals in the high-risk tertile). Similar results were
237 obtained with simulations where the cognitive decline was assessed with the MMSE (Fig.
238 S14).

239 After controlling for demographic covariates, medium- and high-risk tertiles for PVS
240 markers were not significantly associated with amyloid or tau positive status (Table S15),
241 suggesting that screening non-demented participants according to our PVS markers is
242 not linked to Alzheimer disease biomarkers. On the other hand, medium- and high-risk
243 tertiles for P-WML volume, cortical thickness, and grey matter volume were associated
244 with amyloid positive status (Table S15).

245

246 Discussion

247 We developed a novel, fully automated, and robust algorithm to obtain unbiased,
248 quantitative metrics of PVS from clinical brain MRI T1-weighted images. We
249 demonstrated that our method provides accurate segmentations with high inter-scanner
250 and inter-field-strength reproducibility. These characteristics allowed us to apply this
251 algorithm to the brain MRI scans of 10,004 subjects whose data were pooled from three
252 publicly available studies performed in the United States and Canada. We found that after
253 controlling for demographic and clinical covariates, lower PVS count and higher mean
254 PVS diameter were significantly associated with a dose-response higher risk of
255 developing dementia, and with accelerated brain atrophy. The robustness and reliability

256 of these results is related to the large sample size, the use of individual-level data and
257 consistent approaches for covariate adjustments and modeling, and the consistency
258 across multiple sensitivity analyses. These data show that PVS may represent a predictor
259 of dementia.

260 Perivascular spaces represent a critical component of the glymphatic system, a
261 system thought to be responsible for brain clearance of toxic and waste metabolites.²⁷ A
262 larger perivascular diameter might indicate alterations in the glymphatic flow and
263 impairment of the clearance process, with subsequent accumulation of neurotoxic protein
264 aggregates in the brain.^{25,28,29} In agreement with preclinical studies showing a relationship
265 between glymphatic system and blood flow^{25,26}, we found that PVS diameter was
266 inversely correlated with cerebral blood flow. On the other hand, PVS count was positively
267 correlated with brain perfusion, with a higher PVS count also associated with lower risk
268 of dementia and slower brain atrophy. Since the PVS count obtained with our method
269 included any MRI-visible PVS, regardless of whether they could be considered enlarged
270 or not, PVS count may be linked to brain perfusion rather than to glymphatic dysfunction.
271 A low PVS count might indicate cerebral hypoperfusion, a factor found associated with
272 cognitive decline and brain atrophy.³⁰⁻³³

273 Studies prior to ours performed manual visual assessment of perivascular spaces,
274 a significant impediment for large studies and clinical trials, with serious concerns
275 regarding inter- and intra-rater variability. This has led to mixed conclusions on the
276 relationship between PVS and dementia. For example, previous meta-analyses
277 investigated the relationship between WM-PVS and risk of dementia, but the results were
278 conflicting, with significant heterogeneity between studies, variability in methods, and

279 inconsistent adjustment for confounding factors.^{1,34,35} Other studies in smaller cohorts
280 also reported diverging results: some showed an association between perivascular space
281 enlargement and higher risk of dementia,^{36,37} while others found no increased risk³⁸ or
282 increased risk of vascular dementia only.³⁹ Importantly, in all these studies the manual
283 visual assessment prevented a quantitative analysis of the blood vessels with small/non-
284 enlarged perivascular spaces, a limitation eliminated by our novel algorithm. Moreover,
285 visual readings typically do not consider in their assessment the total intracranial volume,
286 a factor strongly associated with PVS⁹ and that we controlled for in all our models.

287 Our novel MRI PVS markers required only a commonly acquired volumetric T1-
288 weighted sequence, were computed in a fully-automated fashion, and showed excellent
289 inter-scanner and test-retest reproducibility. These features may allow for our PVS
290 markers to be readily implemented in clinical practice, as well as retrospective analyses
291 of currently available brain MRI data. As we showed in our clinical trial simulations, their
292 use may reduce the cost and duration of clinical trials for dementia prevention and
293 treatment by facilitating the identification and enrollment of individuals with increased risk
294 of cognitive decline. Indeed, we found that after screening out participants based on our
295 PVS markers, there was a substantial reduction in the minimal number of individuals
296 required for detecting the intervention effect, suggesting an increase in the power of the
297 trial. Importantly, medium and high-risk tertiles of our PVS markers were not linked to
298 positive amyloid and tau status, in contrast with WML and atrophy markers, indicating
299 that the selection of individuals based on our PVS markers is independent of Alzheimer
300 disease biomarker status. In the case of trials for treatments specifically targeting
301 Alzheimer disease hallmark pathology such as amyloid- β and tau (i.e., enrolling

302 individuals positive for amyloid- β and/or tau), these PVS markers would allow to identify
303 and exclude individuals at high risk of vascular/perivascular co-pathology, enhancing the
304 trial for a more homogenous cohort of preclinical Alzheimer disease. Early detection of
305 an increased risk of dementia could also motivate individuals to adopt healthy lifestyle
306 modifications, encouraging healthcare professionals to implement preventive measures
307 and initiate timely treatments and support, thereby improving patient and family member
308 quality of life. Finally, these novel MRI markers open new opportunities to robustly
309 investigate perivascular spaces *in vivo* in a variety of other neurological conditions and
310 treatment paradigms, allowing to gain new insights on the human brain vasculature and
311 lymphatics.

312 We acknowledge the following limitations in our study. First, our analytic approach
313 allowed us to reduce the degree of heterogeneity across studies, but some heterogeneity
314 remained, intrinsic to the original study design, such as the health profile of participants
315 and availability and type of information on covariates. Second, we could not assess the
316 potential role of residual confounding factors, such as diet and socioeconomic status,
317 which were not available in the analyzed databases. Third, as we were restricted to
318 populations recruited by the original studies, our cohort comprised mainly white
319 participants, and increased representation of other racial and ethnic groups would be
320 critical to generalization. Fourth, we cannot exclude that small lesions with vascular shape
321 may be included in our PVS segmentation masks. Nevertheless, the influence of these
322 potential lesions to our statistical analyses may be considered negligible, since even a
323 few lesions in a single subject would represent a very small proportion of the total PVS
324 count estimated in that subject (interquartile range of WM-PVS and BG-PVS per subject

325 in our study were 339-530 and 106-166, respectively). Finally, we could not discriminate
326 whether our PVS metrics refer to periarteriolar or perivenous compartment. However,
327 previous studies have shown that the majority of the MRI-visible PVS overlap with
328 arterioles,⁴⁰⁻⁴² therefore it is reasonable to assume that the PVS metrics in our analysis
329 refer mostly to arterioles and their periarteriolar compartment.

330 In conclusion, using our novel, fully-automated, robust algorithm for assessing
331 perivascular spaces in the cerebral white matter and basal ganglia, we found a significant
332 linear association of low PVS count and high PVS diameter with increased risk of
333 dementia and accelerated brain atrophy. These results support a link between PVS and
334 cognitive impairment, opening new opportunities to risk-stratify individuals for clinical trial
335 enrollment, early healthcare interventions to combat dementia, and accelerated research
336 in human brain glymphatics.

337 Online Methods

338 Study Population

339 We combined data from three observational community-based studies: the Alzheimer's
340 Disease Neuroimaging Initiative (ADNI)⁴³ (MRI data downloaded on March 2023), the
341 National Alzheimer's Coordinating Center (NACC) database⁴⁴ (December 2022 data
342 freeze), and the Open Access Series of Imaging Studies (OASIS-3)⁴⁵ (Data release 2.0,
343 July 2022). Enrolled subjects include both cognitively unimpaired individuals and patients
344 with cognitive impairment and dementia. All participants undergo standardized clinical
345 and neuropsychological examination. All the studies obtained institutional review board
346 approval and written informed consent from all participants.

347 We included in our analysis all participants who underwent 1) at least one clinical visit
348 with cognitive assessment data available and 2) a brain MRI scan including an
349 unenhanced 3-dimensional T1-weighted sequence within 12 months from the baseline
350 clinical visit. In the analysis investigating the risk of dementia, and in the simulated clinical
351 trials, only baseline non-demented subjects with at least 1 follow-up clinical visit were
352 included (definition of dementia is described in the following section). In the analysis of
353 PVS and brain atrophy trajectories assessed with MRI, only baseline non-demented
354 subjects with at least 1 follow-up MRI scan were included.

355 Specific details on the individual study designs and enrollment criteria are provided below.

356

357

358 *ADNI*

359 ADNI is a longitudinal multicenter study conducted in the United States and Canada to
360 develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and
361 tracking of Alzheimer's disease (AD). ADNI began in 2004 and enroll cognitively
362 unimpaired or impaired subjects between 55 and 90 years of age (inclusive) with a study
363 partner to provide an independent evaluation of functioning.⁴⁶ All subjects could not have
364 any medical contraindications to Magnetic Resonance Imaging (MRI), could not be
365 enrolled in other trials or studies concurrently, and could not take any medication that
366 could affect cognitive function.⁴⁶ All subjects had to have Hachinski Ischemic Score of
367 less than or equal to 4;⁴⁷ permitted medications stable for 4 weeks prior to screening; a
368 Geriatric Depression Scale score of less than 6;⁴⁸ a study partner with 10 or more hours
369 per week of contact either in person or on the telephone and who could accompany the
370 participant to the clinical visits; visual and auditory acuity adequate for neuropsychological
371 testing; good general health with no diseases precluding enrollment; 6 grades of
372 education or work history equivalent; and ability to speak English or Spanish fluently.
373 Women had to be sterile or 2 years past childbearing potential.

374 At the screening visit, all subjects were required to provide informed consent as
375 compatible with the local sites (Institutional Review Board regulations). In addition, all
376 subjects provided demographics, family history, and medical history. All subjects were
377 given a physical examination and a neurologic examination, and vital signs were
378 recorded. The haplotype of apolipoprotein E (APOE) gene was assessed on blood
379 samples. Cerebrospinal fluid samples were collected in a subsample of the participants:
380 Amyloid- β_{1-42} , total Tau, and phosphorylated Tau₁₈₁ measurements were completed using

381 the Roche Elecsys Cobas E601 fully automated immunoassay platform at the ADNI
382 biomarker core (University of Pennsylvania) and were available for 61.3%, 61.2%, and
383 61.2% of the participants included in our analysis.

384 Data on amyloid tracers uptake on Positron Emission Tomography (PET), including
385 florbetapir (AV-45), florbetaben (FBB), and Pittsburgh compound B (PiB), were available
386 in 66.7% of participants. Quantitative measurements of standardized uptake value ratio
387 (SUVR) were provided by the ADNI PET core (University of California, Berkeley) following
388 protocols described in the ADNI website ([https://adni.loni.usc.edu/methods/pet-analysis-](https://adni.loni.usc.edu/methods/pet-analysis-method/)
389 [method/](https://adni.loni.usc.edu/methods/pet-analysis-method/)).

390 Participants were classified as amyloid-positive based on abnormal amyloid level
391 detected on cerebrospinal fluid (<1098 pg/ml)⁴⁹ or PET (thresholds recommended in the
392 ADNI PET core documentation: AV-45 >1.11 ,⁵⁰ FBB >1.08 ,⁵¹ PiB >1.5 ⁵²), and as tau-
393 positive based on abnormal level of total tau (>242 pg/ml) or phosphorylated tau (>19.2)
394 on cerebrospinal fluid.⁴⁹

395 Quantitative measurements of cerebral blood flow in units of ml/100mg/min from Arterial
396 Spin Labeling MRI were available in a subsample of 1154 scans acquired on 450
397 subjects, and were performed by the University of California, San Francisco, following
398 protocols described in the ADNI website. The Arterial Spin Labeling techniques included
399 223 3D pseudo-continuous arterial spin labeling (pCASL) and 931 pulsed arterial spin
400 labeling (PASL, 918 2D and 13 3D). We used these measurements in an exploratory
401 analysis to assess the correlation between cerebral blood flow and the corresponding
402 WM-PVS count estimated with our novel algorithm, while controlling for age, sex, race,
403 educational level, body mass index, history of diabetes, cardio-/cerebro-vascular disease,

404 hypertension, dyslipidemia, family history of dementia, the employed arterial spin labeling
405 technique, the total intracranial volume and the volume of the region where cerebral blood
406 flow was assessed.

407

408 *NACC*

409 The NACC database comprises data collected from the Alzheimer's Disease Centers in
410 the United States funded by the National Institute on Aging. From 2005 to the present,
411 these centers have been contributing data to the Uniform Data Set using a prospective,
412 standardized, and longitudinal clinical evaluation of the enrolled subjects, including both
413 cognitively unimpaired individuals and patients with cognitive impairment and dementia.
414 Participants are enrolled on a referral or volunteer basis and undergo a complete
415 examination yielding demographic data, neuropsychological testing scores, and clinical
416 diagnosis. The haplotype of APOE is run independently by each Alzheimer's Disease
417 Center and reported in the NACC database. Cerebrospinal fluid samples were collected
418 in a subsample of the participants: Amyloid- β_{1-42} , total Tau, and phosphorylated Tau₁₈₁
419 measurements were available in 363 (including 206 obtained through enzyme-linked
420 immunosorbent assay, ELISA, and 157 through Luminex), 355 (including 193 ELISA and
421 162 Luminex), and 349 (including 192 ELISA and 157 Luminex) participants. A clinical
422 report of abnormal level of amyloid and tau in cerebrospinal fluid was also available in 96
423 and 91 participants, respectively. Amyloid PET scans were available in 206 participants
424 (111 AV-45 and 95 FBB) and were visually assessed for amyloid positivity by an
425 experienced physician-scientist. A clinical report of abnormal uptake of amyloid and tau
426 tracers in PET were also available in 432 and 26 participants, respectively. Participants

427 were classified as amyloid-positive based on abnormal amyloid level detected on
428 cerebrospinal fluid (<570 pg/ml for ELISA⁵³ or <192 pg/ml for Luminex⁵⁴) or on PET
429 (visually) or as indicated in the clinical report, and as tau-positive based on abnormal level
430 of total tau (>412 pg/ml for ELISA⁵³ and >93 pg/ml for Luminex⁵⁴) or phosphorylated tau
431 (>78 pg/ml for ELISA⁵³ and >23 pg/ml for Luminex⁵⁴) on cerebrospinal fluid or as indicated
432 in the clinical report.

433

434 *OASIS*

435 OASIS-3 is a retrospective compilation of data collected over the course of 15 years as
436 part of research studies at Washington University in St. Louis.⁴⁵ Participants were
437 recruited from the community via flyers, word of mouth, and community engagements.⁴⁵
438 Enrolled participants included individuals considered generally healthy or without medical
439 conditions that precluded longitudinal participation or contraindications to study
440 procedures, such as MRI and lumbar puncture.⁴⁵ Participants underwent clinical
441 assessments which comprised collection of medical and family history, physical
442 examination, and neuropsychological evaluation.⁴⁵ No cerebrospinal fluid data were
443 available for the participants included in our analysis. Data on amyloid and tau tracers
444 uptake on PET were available in 73.3% and 31.2% of participants, respectively. Amyloid
445 tracers included AV-45 in 336 cases and PiB in 656 cases, whereas the employed tau
446 tracer was Flortaucipir (18F-AV-1451). Quantitative measurements of the tracer uptake
447 were provided in OASIS-3. The acquisition and processing protocols are fully described
448 in the OASIS-3 documentation ([https://www.oasis-brains.org/files/OASIS-](https://www.oasis-brains.org/files/OASIS-3_Imaging_Data_Dictionary_v2.3.pdf)
449 [3_Imaging_Data_Dictionary_v2.3.pdf](https://www.oasis-brains.org/files/OASIS-3_Imaging_Data_Dictionary_v2.3.pdf)). We used the cutoff values recommended in the

450 OASIS-3 documentation to classify participants as amyloid-positive (Centiloid AV-
451 45>20.6 or Centiloid PiB>16.4) and as tau-positive (AV-1451 Tauopathy>1.22).

452

453 Assessment of cognitive status and dementia

454 In all three cohorts, the Clinical Dementia Rating (CDR) assessment⁵⁵ was performed
455 through standardized interview with the participant and a knowledgeable informant. Six
456 categories of cognitive functioning (memory, orientation, judgment and problem solving,
457 community affairs, home and hobbies, and personal care) were assessed. We used the
458 standard CDR global score cutoff value of 1 to classify participants as demented (1 and
459 above) or non-demented. The Mini-Mental Status Examination⁵⁶ (MMSE) scores were
460 available in a subgroup of 7046 participants and were used only in sensitivity analyses.
461 MMSE evaluates orientation, memory, attention, concentration, naming, repetition,
462 comprehension, and ability to create a sentence and to copy 2 overlapping pentagons.⁵⁶
463 We did not categorize participants based on the clinical diagnosis when available due to
464 the lack of scientific consensus and the variability in the diagnostic criteria adopted within
465 and across the studies.

466

467 MRI data processing

468 MRI data were acquired with a variety of 1.5- and 3-Tesla MRI scanners and sequences
469 (Table S1). All T1-weighted images were processed using the *recon-all* module of the
470 freely available FreeSurfer software package (v7.4),⁵⁷ which resampled all the images to
471 1 mm isotropic resolution and performed an atlas-based brain parcellation. The

472 longitudinal processing scheme was used for estimating brain atrophy (grey and white
473 matter volumes, and cortical thickness) longitudinally.⁵⁸ White matter lesions (WML) were
474 segmented with a previously validated approach on T1-weighted images.²⁴ We classified
475 as periventricular WML the clusters of WML adjacent to the lateral ventricles; the
476 remaining clusters of WML were classified as deep WML.

477

478 Robust PVS segmentation method development and validation

479 The filter developed by Frangi et al.¹⁶ enhances tubular, vessel-like structures on a
480 gray-scale image and assigns a “vesselness” value to each voxel $\mathcal{V}(s)$ from
481 eigenvectors λ of the Hessian matrix \mathcal{H} of the image as:

$$482 \mathcal{V}(s) = \begin{cases} 0 & \text{if } \lambda_2 > 0 \text{ or } \lambda_3 > 0, \\ \left(1 - \exp\left(-\frac{\mathcal{R}_A^2}{2\alpha^2}\right)\right) \exp\left(-\frac{\mathcal{R}_B^2}{2\beta^2}\right) \left(1 - \exp\left(-\frac{s^2}{2c^2}\right)\right) & \text{otherwise} \end{cases}$$

483 Where, $\mathcal{R}_A = \frac{|\lambda_1|}{|\lambda_2|}$, $\mathcal{R}_B = \frac{|\lambda_1|}{\sqrt{|\lambda_2\lambda_3|}}$, $S = \|\mathcal{H}\|$.

484 We and others previously implemented and validated this filter for the segmentation of
485 MRI-visible vascular and perivascular spaces on T1-weighted images using the default,
486 recommended parameters of $\alpha=0.5$, $\beta=0.5$, and c set to half the value of the maximum
487 Hessian norm.^{12,13,59} This approach requires the user to identify a threshold on the
488 vessel map generated by the filter to define the vessel-like structures: values above that
489 threshold (i.e., with high “vesselness” values) are considered vascular and perivascular
490 spaces, and values below are excluded. However, since the scale of the “vesselness”
491 values generated by the filter differs from image to image (Figure S1 A) depending on
492 the signal intensity values of the input image,¹⁶ and since the signal intensity values on

493 T1-weighted images are represented in arbitrary units which may vary depending on the
494 MRI machine and its calibration, this approach lacks inter-scanner reproducibility^{1,9,16–18}
495 (Fig. S1 B) and is potentially biased even in longitudinal studies. To overcome this
496 issue, we developed and validated a novel approach for the segmentation of MRI-visible
497 vessel-like structures applicable to virtually any type of T1-weighted image.

498 The MRI data used for the method development and validation were acquired as part of
499 the Biomarkers Consortium for Vascular Contributions to Cognitive Impairment and
500 Dementia (MarkVCID),⁶⁰ the Alzheimer Disease Neuroimaging Initiative (ADNI),⁴³ and
501 the Human Connectome Project (HCP development,⁶¹ young adults,⁶² and aging⁶³), and
502 included:

- 503 a) the inter-scanner reproducibility dataset: 19 participants who underwent four
504 brain MRI scans within an interval of 3 to 90 days on four different 3-Tesla MRI
505 scanners (General Electric system 750W, Philips Achieva dStream, Siemens
506 Prisma, and Siemens TIM Trio) from MarkVCID;
- 507 b) the inter-field-strength reproducibility dataset: 299 MRI sessions from 115 ADNI
508 participants who underwent in each session two brain MRI scans on the same
509 day with a 1.5- and a 3-Tesla scanner;
- 510 c) the test-retest dataset: 39 participants from MarkVCID who underwent two brain
511 MRI scans on the same MRI scanner using the same protocol within an interval
512 of 1 to 14 days;
- 513 d) the biological validation dataset: 2163 healthy individuals from the HCP whose
514 MRI-visible vascular and perivascular spaces have been studied extensively^{21–23},
515 providing a reference for verifying established associations.

516 Tables S17 and S18 include the details for the baseline characteristics of the analyzed
517 individuals and the MRI protocols employed in each of the above datasets, respectively.
518 Our novel approach is based on the observation that the total number of voxels with
519 non-zero vesselness value obtained from the Frangi filter applied on T1-weighted
520 images is:

- 521 1) consistent across brain images of the same participant acquired with different
522 MRI scanners (inter-scanner and inter-field-strength reproducibility, Figure S2 A
523 and B);
- 524 2) consistent across brain images of the same participant acquired on two different
525 MRI sessions with the same MRI scanner and protocol (test-retest repeatability,
526 Figure S2 C);
- 527 3) Significantly associated with age, sex, and body mass index (Figure S2 D-F) as
528 previously described for PVS.^{21–23}

529
530 Therefore, we hypothesized that the value of the voxel corresponding to a single,
531 specific percentile of the total number of voxels with non-zero “vesselness” values could
532 be used as a threshold for consistently and robustly segmenting MRI-visible vessel-like
533 structures across different types of T1-weighted images (Figure S1 C-D). We identified
534 this percentile to be 85%, based on the average ratio between the number of voxels that
535 we previously segmented as vascular and perivascular spaces in the HCP dataset^{21,22}
536 and the corresponding total number of voxels with non-zero vesselness value.
537 In each individual vesselness map generated by the Frangi filter, the vesselness value
538 corresponding to the 85th percentile of the total number of non-zero voxels was

539 automatically computed: the voxels with vesselness value above this threshold were
540 retained and binarized to make the PVS mask, whereas those below or equal to the
541 threshold were excluded. To improve the specificity of the PVS segmentation,^{17,59} the
542 Frangi filter was applied on FreeSurfer's white matter mask with the following
543 modifications: the voxels labeled as corpus callosum by FreeSurfer were excluded;
544 periventricular areas were excluded by subtracting FreeSurfer's lateral ventricle binary
545 mask enlarged by 3 units from the white matter binary mask; white matter lesions
546 (WML) segmented with SAMSEG²⁴ were also excluded. Finally, we used MATLAB's
547 *regionprops3* function with the default 26-connected neighborhood definition to compute
548 PVS count and mean diameter across all PVS clusters with in-plane size of at least 2
549 voxels detected in the modified white matter mask of each subject.

550 Accuracy of the PVS segmentation was assessed via visual inspection and quantified
551 with the Dice similarity coefficient using as a reference the PVS masks obtained with an
552 established and previously validated technique applied on the HCP dataset (Fig.
553 S3A).^{12,13,17,23} The Dice similarity coefficient ranges from 0, indicating no spatial overlap
554 between two sets of binary segmentation masks, to 1, indicating complete overlap.

555 The robustness of the PVS metrics assessed in our study (i.e., PVS count and PVS mean
556 diameter) across different MRI scanners (inter-scanner and inter-field-strength
557 reproducibility) and sessions (test-retest repeatability) was assessed with the intraclass
558 correlation coefficients, ranging from 0 to 1, where a higher value indicates higher
559 agreement between the compared modalities (Fig. S4). Similar evaluations were also
560 performed for WML metrics (Fig. S6)

561 Since typically FLAIR and T2-weighted images are considered more sensitive to WML
562 and PVS, respectively,^{8,9} due to a higher contrast between the cerebral parenchyma and
563 the WML/PVS, we also evaluated the suitability of assessing WML and PVS with only the
564 T1-weighted images in two ways: 1) we measured the correlation between the number of
565 WML/PVS voxels measured on T1-weighted versus FLAIR/T2-weighted images, to
566 determine the strength and direction of their relationship (Fig. S5); 2) to confirm the spatial
567 agreement of the WML/PVS voxels across the two modalities, we measured the overlap
568 of the WML/PVS voxels identified on T1-weighted images with the WML/PVS voxels (and
569 the adjacent 3 voxels to account for any residual misalignment between modalities)
570 identified from FLAIR/T2-weighted images rigidly registered to the corresponding T1-
571 weighted images.

572

573 Statistical analysis

574 All the models and simulations described below were adjusted for intracranial volume and
575 the following baseline factors (as reported on the documented clinical assessment and
576 subject health history): age, sex, educational level, race, body mass index, CDR global
577 score, family history of dementia (positive if any of the participants' parents were reported
578 to have dementia), and history of hypertension, dyslipidemia, diabetes, and cardio-
579 /cerebro-vascular disease (i.e., any of the following: heart failure, angina, cardiac arrest,
580 stent placement, coronary artery bypass, pacemaker, defibrillator, heart valve
581 replacement or repair, stroke, transient ischemic attack). These factors were all available

582 for more than 97% participants. We used missing indicators for handling missing values
583 in the covariates.

584 The associations of our PVS markers with cognitive status (non-dementia versus
585 dementia) and the other covariates at the baseline visit were assessed with general linear
586 models stratified according to study. The association of our PVS markers at the baseline
587 with subsequent risk of developing dementia was assessed in each study independently
588 with Cox proportional-hazards models and the results were integrated using a random-
589 effects meta-analysis to account for potential differences among the studies (two-stage
590 pooled analysis). Inter-study heterogeneity was assessed statistically with the I^2 . Person-
591 time was calculated from the baseline clinical visit until the visit where the dementia was
592 documented or the last clinical visit, whichever occurred first. The proportional-hazard
593 assumptions were verified by assessing the relationship between Schoenfeld residuals
594 and time.⁶⁴ Additionally, we analyzed these associations by combining in the same model
595 all the individual-level data (simple pooled analysis), stratified according to study and
596 adjusted for the same covariates, and used penalized splines to assess their deviation
597 from linearity.⁶⁵ In addition to the covariates used in all the other models, the linear models
598 and Cox-regression models above were also controlled for the time interval between the
599 MRI scan and the clinical visit of the cognitive assessment at the baseline.

600 Linear mixed-effects models with random intercepts and slopes for each participant were
601 used to estimate the longitudinal trajectories of grey matter volume, cortical thickness,
602 and white matter volume according to baseline PVS count or mean diameter. In addition
603 to the covariates used in all the other models, the linear mixed-effects models were also
604 adjusted for the value of the dependent variable at the baseline, and the following

605 characteristics of the MRI scanner that may influence the longitudinal estimation of brain
606 atrophy: field strength, manufacturer, and intra-individual consistency of the protocol used
607 for the longitudinal MRI acquisitions (consistent versus non-consistent protocol).
608 Interaction terms between time and all predictors were included as well to estimate the
609 marginal per-year effects of each predictor. Linear mixed-effects models with random
610 intercepts and slopes for each participant were also used to estimate and compare the
611 longitudinal trajectories of PVS and WML markers in non-demented individuals who
612 converted to dementia versus non-converters.

613 Sensitivity analyses for all the models above included: 1) the individual assessment of
614 other potential confounding factors available only in a subsample of the participants
615 (92.6% history of tobacco smoking, 90.0% Apolipoprotein E alleles, 39.0% amyloid- β and
616 24.7% tau status as assessed on cerebrospinal fluid and/or Positron-Emission
617 Tomography); 2) the use of MMSE rather than CDR for the cognitive evaluation (available
618 in 70.3% of the participants); 3) the assessment of MRI acquisition artifacts or factors that
619 could have influenced the estimation of the vascular markers. In sensitivity
620 analyses, hazard ratios were estimated from Cox models with stratification according to
621 study cohort (simple pooled analysis) owing to smaller sample sizes in the individual
622 studies.

623 To evaluate the potential utility of PVS markers as a screening tool in clinical trials, we
624 computed the sample size needed to detect improvements in cognitive decline
625 trajectories when restricting the sample based on the baseline values of the marker, and
626 compared it to the sample size requested without any restriction. The clinical trials were
627 simulated with 1:1 allocation of active treatment and placebo, assuming a 30% treatment

628 effect on cognition over time, a trial duration of 48 months, and cognitive testing every 12
629 months. 500 simulations were generated with bootstrap iteration.

630 All the analyses were based on *a priori* hypotheses, but to account for two variables of
631 interest (PVS count and mean diameter), we present P values that were corrected for
632 multiple comparisons with the use of the Holm–Bonferroni procedure.⁶⁶ In brain regional
633 analyses, the correction for multiple comparisons was performed across all the
634 analyzed regions. All statistical analyses were performed in R v4.3.3. The following R
635 packages were used for the statistical analyses and generation of the plots: *survival*
636 was used for fitting the Cox proportional-hazards models;⁶⁷ *meta* was used for the meta-
637 analysis;⁶⁸ *lmer4* was used for fitting the non-linear mixed models;⁶⁹ *ggeffects* was used
638 for estimating the marginal effects in the non-linear mixed models;⁷⁰ *longpower* was
639 used for the simulation of clinical trials;⁷¹ *ggseg* was used for generating the plots with
640 the brain statistics;⁷² *ggplot2* was used for generating all the other plots.⁷³

641 Acknowledgements

642 The authors thank all the participants and personnel involved in the data collection.

643 The authors G.B. and M.H. are supported by a grant (U54CA261717 to Dr. Hayden-
644 Gephart) from the National Institutes of Health (NIH), J.C. is supported by grants
645 RF1MH123223, R01AG070825, and R01NS128486 from the NIH.

646 The authors thank Dr. Michael Greicius, M.D., from the Department of Neurology at
647 Stanford University for valuable discussion of the manuscript.

648 The image computing resources provided by the Laboratory of Neuro Imaging Resource
649 (LONIR) at the University of Southern California are supported in part by NIH National
650 Institute of Biomedical Imaging and Bioengineering (NIBIB) grant P41EB015922.

651 Data used in preparation of this article include data obtained from the MarkVCID
652 consortium. A complete listing of MarkVCID investigators can be found at:
653 www.markvcid.org.

654 **Disclosures:** G.B. is inventor on a patent application related to this work filed by
655 Stanford University. The other authors declare that they have no competing interests.

656 **ADNI:** Data collection and sharing for this project was funded by the Alzheimer's Disease
657 Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and
658 DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded
659 by the National Institute on Aging, the National Institute of Biomedical Imaging and
660 Bioengineering, and through generous contributions from the following: AbbVie,
661 Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech;

662 BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai
663 Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La
664 Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO
665 Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson &
666 Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck &
667 Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies;
668 Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda
669 Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of
670 Health Research is providing funds to support ADNI clinical sites in Canada. Private
671 sector contributions are facilitated by the Foundation for the National Institutes of Health
672 (www.fnih.org). The grantee organization is the Northern California Institute for Research
673 and Education, and the study is coordinated by the Alzheimer's Therapeutic Research
674 Institute at the University of Southern California. ADNI data are disseminated by the
675 Laboratory for Neuro Imaging at the University of Southern California.

676 **NACC:** The National Alzheimer's Coordinating Center (NACC) database is funded by
677 NIA/NIH Grant U24 AG072122. NACC data are contributed by the NIA-funded ADRCs:
678 P30 AG062429 (PI James Brewer, MD, PhD), P30 AG066468 (PI Oscar Lopez, MD), P30
679 AG062421 (PI Bradley Hyman, MD, PhD), P30 AG066509 (PI Thomas Grabowski, MD),
680 P30 AG066514 (PI Mary Sano, PhD), P30 AG066530 (PI Helena Chui, MD), P30
681 AG066507 (PI Marilyn Albert, PhD), P30 AG066444 (PI John Morris, MD), P30
682 AG066518 (PI Jeffrey Kaye, MD), P30 AG066512 (PI Thomas Wisniewski, MD), P30
683 AG066462 (PI Scott Small, MD), P30 AG072979 (PI David Wolk, MD), P30 AG072972
684 (PI Charles DeCarli, MD), P30 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI

685 David Bennett, MD), P30 AG072978 (PI Neil Kowall, MD), P30 AG072977 (PI Robert
686 Vassar, PhD), P30 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald
687 Petersen, MD, PhD), P30 AG079280 (PI Eric Reiman, MD), P30 AG062422 (PI Gil
688 Rabinovici, MD), P30 AG066511 (PI Allan Levey, MD, PhD), P30 AG072946 (PI Linda
689 Van Eldik, PhD), P30 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973 (PI
690 Russell Swerdlow, MD), P30 AG066506 (PI Todd Golde, MD, PhD), P30 AG066508 (PI
691 Stephen Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30
692 AG072947 (PI Suzanne Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30
693 AG066546 (PI Sudha Seshadri, MD), P20 AG068024 (PI Erik Roberson, MD, PhD), P20
694 AG068053 (PI Justin Miller, PhD), P20 AG068077 (PI Gary Rosenberg, MD), P20
695 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD), P30
696 AG072959 (PI James Leverenz, MD).

697 **OASIS:** Data were provided in part by the Open Access Series of Imaging Studies
698 (OASIS) OASIS-3: Longitudinal Multimodal Neuroimaging: Principal Investigators: T.
699 Benzinger, D. Marcus, J. Morris; NIH P30 AG066444, P50 AG00561, P30 NS09857781,
700 P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352, NIH
701 P30 AG066444, AW00006993.

702 AV-45 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of
703 Eli Lilly.

704 AV-1451 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary
705 of Eli Lilly.

706 **MarkVCID:** MarkVCID was launched in 2016 by the NIH's National Institute of
707 Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA), and

708 consists of research groups across the United States. The primary goal of MarkVCID is
709 to generate a suite of validated biomarkers ready for application to clinical trials aimed
710 at identifying disease-modifying therapies for VCID. For up-to-date information, see
711 www.markvcid.org. Data collection and sharing was funded by NINDS/NIA as part of the
712 Biomarkers Consortium for Vascular Contributions to Cognitive Impairment and
713 Dementia (MarkVCID): U24NS100591, UH2NS100599, UH2NS100605,
714 UH2NS100588, UH2NS100608, UH2NS100606, UH2NS100598, UH2NS100614.

715 **Human Connectome Project:** Data were provided in part by the Human Connectome
716 Project (HCP), WU-Minn Consortium (1U54MH091657) funded by the 16 NIH Institutes
717 and Centers that support the NIH Blueprint for Neuroscience Research; and by the
718 McDonnell Center for Systems Neuroscience at Washington University. Data from
719 HCP-Aging cohort was supported by the National Institute on Aging of the
720 National Institutes of Health under Award Number U01AG052564. Data from HCP-
721 Development cohort was supported by the National Institute of Mental Health of
722 the National Institutes of Health under Award Number U01MH109589. The content is
723 solely the responsibility of the authors and does not necessarily represent the official
724 views of the National Institutes of Health. MRI and clinical data can be accessed from
725 <https://www.humanconnectome.org>.

726

727 Author contributions

728 Giuseppe Barisano, Jeiran Choupan and Melanie Hayden-Gephart designed the study.

729 Giuseppe Barisano developed the method for robust perivascular space segmentation.

730 Giuseppe Barisano processed the MRI data, gathered the demographic and clinical

731 data, and performed the statistical analysis. Giuseppe Barisano, Jeiran Choupan and

732 Melanie Hayden-Gephart vouch for the data and the analysis. Giuseppe Barisano

733 developed the interactive website. Giuseppe Barisano wrote the first draft of the

734 manuscript. All the authors contributed to result interpretation and manuscript editing.

735 All the authors agreed to publish the paper.

736

737 Data used in preparation of this article were obtained from the Alzheimer's Disease

738 Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators

739 within the ADNI contributed to the design and implementation of ADNI and/or provided

740 data but did not participate in analysis or writing of this report.

741

742 Figures & Tables

Characteristic	Overall (N=10,004)	ADNI (N=2621)	NACC (N=6029)	OASIS (N=1354)
Age at baseline – yr	71.1 ± 9.7	72.9 ± 7.5	70.6 ± 10.5	70.2 ± 9.2
Female – %	56.6	48.4	60.7	54.8
Education – yr	15.7 ± 3.1	16.1 ± 2.7	15.5 ± 3.2	15.8 ± 2.7
Race – %				
White	84.7	87.8	83.6	83.5
Black	11.6	7.7	12.5	15.1
Asian	0.8	0.2	1.2	0
American Indians	1.8	2.3	1.8	0.6
More than one reported	0.4	1.3	0	0.2
Body Mass Index – kg/m ²	27.2 ± 5.2	27.1 ± 5.1	27.1 ± 5.2	27.8 ± 5.4
Dyslipidemia – %	52.7	52.9	53.8	47.6
Hypertension – %	47.5	47.6	47.5	47.1
Diabetes – %	12.3	10.3	13.5	10.6
History of cardiovascular/cerebro-vascular disease – %	28	34.1	26	25.1

Family history of dementia – %	51.2	52.5	49.8	55.1
History of tobacco smoking* – %	37.7	24.4	42.5	44.9
APOE* – %				
ε2ε2	0.3	0.3	0.3	0.6
ε2ε3	9.2	7.4	9.7	10.6
ε2ε4	2.4	2.1	2.4	3.3
ε3ε3	49	46.8	50.6	47.3
ε3ε4	31.8	34.1	30.5	32.4
ε4ε4	7.2	9.4	6.5	5.8
A-beta positivity* – %	50.1	62.7	40.6	32.7
Tau positivity* – %	64.7	53.1	45.0	59.2
WM-PVS count	428.0 (339 to 530)	384.0 (306 to 483)	447.0 (358 to 551)	427.0 (344 to 520)
BG-PVS count	133.0 (106 to 166)	107.0 (88 to 143)	143.0 (117 to 174)	132.0 (113 to 156)
WM-PVS mean diameter – mm	2.0 (1.87 to 2.07)	2.0 (1.94 to 2.17)	1.9 (1.86 to 2.03)	2.0 (1.88 to 2.05)
BG-PVS mean diameter – mm	1.6 (1.51 to 1.64)	1.6 (1.55 to 1.71)	1.5 (1.51 to 1.60)	1.6 (1.53 to 1.62)


P-WML volume – mm ³	330.0 (0 to 1613)	596.5 (46 to 1989.50)	230.0 (0 to 1406)	257.5 (0 to 1674.25)
D-WML volume – mm ³	16.0 (1 to 72)	34.0 (7 to 104)	8.0 (0 to 53)	24.0 (4 to 89.75)

743

744 **Table 1. Baseline characteristics of the study population.**

745 Plus–minus values are means \pm standard deviations, entries with parentheses are
746 medians (interquartile range). Data on education were missing for 0.15% of the
747 participants, on race for 0.8%, on body mass index for 2.6%, on dyslipidemia for 1.2%,
748 on hypertension and diabetes for 0.7%, on history of cardio-/cerebro-vascular disease
749 on 0.5%, on family history for dementia for 2.7%. Data from three studies — the
750 Alzheimer’s Disease Neuroimaging Initiative (ADNI), the National Alzheimer’s
751 Coordinating Center (NACC), and the Open Access Series of Imaging Studies (OASIS)
752 — are shown. Race was reported by the participant. *Total number of subjects with
753 available history of tobacco smoking, Apolipoprotein E (APOE) genotype, amyloid-beta
754 status and tau status were 9267, 8599, 3906, and 2466, respectively.

755



757 **Figure 1. Forest plots and spline plots for the Associations of PVS and WML**
758 **markers with Dementia Risk.**


759 In two-stage pooled analyses that combined individual-participant data from three
760 studies (Panels A-F), each additional 100 WM-PVS (Panel A) and 10 BG-PVS (Panel B)
761 were associated with 20% and 9% decrease in dementia risk, each additional 0.1 mm
762 increase in mean WM-PVS (Panel C) and BG-PVS (Panel D) diameter were associated
763 with 9% and 20% increase in dementia risk, and each unit increase of the log-
764 transformed P-WML volume (Panel E) was associated with 13% increase in dementia
765 risk. Log-transformed D-WML volume (Panel F) was not associated with dementia risk.
766 In each graph, the size of the squares indicates the weight given to the study, and the
767 width of the diamond indicates the 95% confidence interval for the overall association
768 estimate. Between-study heterogeneity was statistically assessed with the use of I^2 .

769 The spline analysis of pooled data (Panels G-L) supported a linear association over the
770 range of WM-PVS count (Panel G; 2.5th-97.5th percentile, 206 to 762), BG-PVS count
771 (Panel H; 2.5th-97.5th percentile, 71 to 244), WM-PVS diameter (Panel I; 2.5th-97.5th
772 percentile, 1.77 to 2.30 mm), BG-PVS diameter (Panel J; 2.5th-97.5th percentile, 1.44 to
773 1.79) and P-WMH volume (Panel K; 2.5th-97.5th percentile, 0 to 9.1) within the overall
774 population. Shaded areas indicate 95% confidence intervals, and the red line at 1.0
775 indicates the reference. Box plots at the bottom of the graphs show the distributions of
776 the marker. The vertical bar indicates the median, and the ends of the box the
777 interquartile range; the whiskers extend to values no farther than 1.5 times the
778 interquartile range (which may be past the graphed area).

779

780 Data from three studies — the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the
781 Open Access Series of Imaging Studies (OASIS), and the National Alzheimer’s
782 Coordinating Center (NACC) — are shown. Hazard ratios were estimated from Cox
783 models stratified according to study cohort with adjustment for age, sex, race,
784 educational level, body mass index, CDR global score at the baseline, history of
785 diabetes, cardio-/cerebro-vascular disease, hypertension, dyslipidemia, family history of
786 dementia, intracranial volume and the time interval between the MRI scan and the
787 clinical visit of the cognitive assessment at the baseline.

788




789

790 **Figure 2. Plots for the estimated trajectories of brain atrophy in relation to PVS**
791 **and WML markers.**

792 Top rows in each panel depict the effect of baseline PVS and WML markers on the
793 trajectories of grey matter volume, cortical thickness, and white matter volume (Panels
794 A-C, respectively). For each marker, equally spaced values from the low-risk (red),
795 medium-risk (blue), and high-risk (yellow) tertile are shown (tertile limits in Table S16).
796 Shaded areas indicate 95% confidence intervals. The regional analysis (bottom rows in

797 each panel) across cortical parcellations according to the Desikan-Killiany atlas reports
798 the estimated volume or thickness preserved (positive values in red) or lost (negative
799 values in blue) per year for each additional unit increase in the vascular marker. Only
800 estimated values for regions that remained statistically significant after correction for
801 multiple comparisons (68 comparisons) are shown; non-significant regions are greyed
802 out. See also Tables S11-13 for grey matter volume, cortical thickness, and white
803 matter volume, respectively. Estimates and corrected significance (P values) obtained
804 from fully adjusted linear mixed-effects models with random intercepts and slopes for
805 each individual participant (N=3389 and 14,229 timepoints MRI scans). All models were
806 adjusted for age, sex, race, educational level, body mass index, CDR global score at
807 the baseline, history of diabetes, cardio-/cerebro-vascular disease, hypertension,
808 dyslipidemia, family history of dementia, intracranial volume, the baseline value of the
809 dependent variable (grey matter volume, cortical thickness, or white matter volume),
810 field strength, manufacturer, and intra-individual consistency of the protocol used for the
811 longitudinal MRI acquisitions (consistent versus non-consistent protocol).

812




813

814 **Figure 3. Plots for the estimated longitudinal trajectories of PVS or WML markers**
815 **according to conversion to dementia status.**

816 Estimated longitudinal trajectories of WM-PVS (A-B), BG-PVS (C-D), and WML (E)
817 markers for non-demented individuals who converted to dementia (converters, red) and
818 those that did not convert to dementia (non-converters, cyan). Trajectories are
819 estimated from fully adjusted linear mixed-effect models; the adjusted p-values (P)
820 indicate whether the trajectories are significantly different between the groups after
821 correction for multiple comparisons. Shaded areas indicate 95% confidence intervals.

822 For WM-PVS markers (panels A-B), we estimated in each lobe of the left (L) and right
823 (R) hemispheres the group-effect (expressed as T-value) for the longitudinal trajectories
824 of the corresponding marker: positive values in red indicate significantly higher (i.e., less
825 negative) slopes for non-converters versus converters, whereas negative values in blue
826 indicate significantly lower (i.e., more negative) slopes for non-converters versus
827 converters. Lobes where the longitudinal trajectories were not significantly different
828 between converters and non-converters after correction for multiple comparisons are
829 greyed-out. Estimates and corrected significance obtained from fully adjusted linear
830 mixed-effects models with random intercepts and slopes for each individual participant
831 (N=3389 and 14,229 timepoints MRI scans).

832



833

834 **Figure 4. Barplots for the relative sample size in simulated clinical trials enriched**
835 **using PVS or WML markers.**

836 Relative sample sizes for simulated clinical trials in non-demented individuals pooled
837 from three studies (the Alzheimer’s Disease Neuroimaging Initiative, the Open Access
838 Series of Imaging Studies, and the National Alzheimer’s Coordinating Center). The
839 simulations had statistical power of 80% at $\alpha = .05$ and assumed a 30% treatment effect
840 for slopes in cognitive decline, 1:1 allocation of treatment, total trial length of 48 months,
841 and outcome measures every 12 months. All available longitudinal cognitive data
842 (40,307 cognitive assessments from 7518 non-demented subjects) were used in these
843 fully-adjusted models. All estimates and standard errors are across 500 bootstrap
844 iterations. The reference model (without enrichment and with 100% inclusion) included
845 all the tertiles. In the two enrichment models for each marker (“medium-risk+high-risk

846 tertiles”, red bars; “high-risk only tertile”, blue bars), only participants in the indicated

847 tertiles were included. Tertile limits for each marker are reported in Table S16.

848

849

850

851

852 References

- 853 1. Debette, S., Schilling, S., Duperron, M. G., Larsson, S. C. & Markus, H. S. Clinical
854 Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury: A
855 Systematic Review and Meta-analysis. *JAMA Neurol.* **76**, 81–94 (2018).
- 856 2. Wardlaw, J. M., Smith, C. & Dichgans, M. Small vessel disease: mechanisms and
857 clinical implications. *Lancet Neurol.* **18**, 684–696 (2019).
- 858 3. Arvanitakis, Z., Capuano, A. W., Leurgans, S. E., Bennett, D. A. & Schneider, J.
859 A. Relation of cerebral vessel disease to Alzheimer’s disease dementia and
860 cognitive function in elderly people: a cross-sectional study. *Lancet Neurol.* **15**,
861 934–943 (2016).
- 862 4. Roher, A. E. *et al.* Intracranial atherosclerosis as a contributing factor to
863 Alzheimer’s disease dementia. *Alzheimers. Dement.* **7**, 436 (2011).
- 864 5. Dolan, H. *et al.* Atherosclerosis, dementia, and Alzheimer disease in the Baltimore
865 Longitudinal Study of Aging cohort. *Ann. Neurol.* **68**, 231–240 (2010).
- 866 6. Fu, C. *et al.* Comorbidity in dementia: an autopsy study. *Arch. Pathol. Lab. Med.*
867 **128**, 32–38 (2004).
- 868 7. Beach, T. G. *et al.* Circle of Willis atherosclerosis: association with Alzheimer’s
869 disease, neuritic plaques and neurofibrillary tangles. *Acta Neuropathol.* **113**, 13–
870 21 (2007).
- 871 8. Duering, M. *et al.* Neuroimaging standards for research into small vessel
872 disease—advances since 2013. *Lancet Neurol.* **22**, 602–618 (2023).

- 873 9. Barisano, G. *et al.* Imaging perivascular space structure and function using brain
874 MRI. *Neuroimage* **257**, 119329 (2022).
- 875 10. Schwartz, D. L. *et al.* Autoidentification of perivascular spaces in white matter
876 using clinical field strength T1 and FLAIR MR imaging. *Neuroimage* **202**, (2019).
- 877 11. Rashid, T. *et al.* Deep Learning Based Detection of Enlarged Perivascular Spaces
878 on Brain MRI. *Neuroimage. Reports* **3**, (2023).
- 879 12. Sepehrband, F. *et al.* Image processing approaches to enhance perivascular
880 space visibility and quantification using MRI. *Sci. Rep.* **9**, 12351 (2019).
- 881 13. Ballerini, L. *et al.* Perivascular Spaces Segmentation in Brain MRI Using Optimal
882 3D Filtering. *Sci. Rep.* **8**, 1–11 (2018).
- 883 14. Ramirez, J. *et al.* Imaging the Perivascular Space as a Potential Biomarker of
884 Neurovascular and Neurodegenerative Diseases. *Cell. Mol. Neurobiol.* **36**, 289–
885 299 (2016).
- 886 15. Boespflug, E. L. *et al.* MR Imaging–based Multimodal Autoidentification of
887 Perivascular Spaces (mMAPS): Automated Morphologic Segmentation of
888 Enlarged Perivascular Spaces at Clinical Field Strength. *Radiology* **286**, 632–642
889 (2018).
- 890 16. Frangi, A. F., Niessen, W. J., Vincken, K. L. & Viergever, M. A. Multiscale vessel
891 enhancement filtering. in *Medical Image Computing and Computer-Assisted*
892 *Intervention— Miccai’98*. 1496, **1496**, 130–137 (Springer, Berlin, Heidelberg,
893 1998).
- 894 17. Sepehrband, F. *et al.* Volumetric distribution of perivascular space in relation to

- 895 mild cognitive impairment. *Neurobiol. Aging* **99**, 28–43 (2021).
- 896 18. Caprihan, A. *et al.* A trichotomy method for defining homogeneous subgroups in a
897 dementia population. *Ann. Clin. Transl. Neurol.* **10**, 1802–1815 (2023).
- 898 19. Vernooij, M. W. *et al.* Dementia imaging in clinical practice: a European-wide
899 survey of 193 centres and conclusions by the ESNR working group.
900 *Neuroradiology* **61**, 633–642 (2019).
- 901 20. Insel, P. S. *et al.* Determining clinically meaningful decline in preclinical Alzheimer
902 disease. *Neurology* **93**, E322–E333 (2019).
- 903 21. Barisano, G., Sheikh-Bahaei, N., Law, M., Toga, A. W. & Seppehrband, F. Body
904 mass index, time of day and genetics affect perivascular spaces in the white
905 matter. *J. Cereb. Blood Flow Metab.* **41**, 1563–1578 (2021).
- 906 22. Lynch, K. M., Seppehrband, F., Toga, A. W. & Choupan, J. Brain perivascular
907 space imaging across the human lifespan. *Neuroimage* **271**, 120009 (2023).
- 908 23. Kim, H. G. *et al.* MRI-visible Dilated Perivascular Space in the Brain by Age: The
909 Human Connectome Project. *Radiology* **306**, (2023).
- 910 24. Puonti, O., Iglesias, J. E. & Van Leemput, K. Fast and sequence-adaptive whole-
911 brain segmentation using parametric Bayesian modeling. *Neuroimage* **143**, 235–
912 249 (2016).
- 913 25. Mestre, H. *et al.* Flow of cerebrospinal fluid is driven by arterial pulsations and is
914 reduced in hypertension. *Nat. Commun.* **9**, 4878 (2018).
- 915 26. Holstein-Rønsbo, S. *et al.* Glymphatic influx and clearance are accelerated by
916 neurovascular coupling. *Nat. Neurosci.* **26**, 1042–1053 (2023).

- 917 27. Iliff, J. J. *et al.* A paravascular pathway facilitates CSF flow through the brain
918 parenchyma and the clearance of interstitial solutes, including amyloid β . *Sci.*
919 *Transl. Med.* **4**, 1–11 (2012).
- 920 28. Iliff, J. J. *et al.* Cerebral Arterial Pulsation Drives Paravascular CSF-Interstitial
921 Fluid Exchange in the Murine Brain. *J. Neurosci.* **33**, 18190–18199 (2013).
- 922 29. Kress, B. T. *et al.* Impairment of paravascular clearance pathways in the aging
923 brain. *Ann. Neurol.* **76**, 845–861 (2014).
- 924 30. Hays, C. C., Zlatar, Z. Z. & Wierenga, C. E. The Utility of Cerebral Blood Flow as
925 a Biomarker of Preclinical Alzheimer’s Disease. *Cell. Mol. Neurobiol.* **36**, 167–179
926 (2016).
- 927 31. Duan, W. *et al.* Cerebral Blood Flow Is Associated with Diagnostic Class and
928 Cognitive Decline in Alzheimer’s Disease. *J. Alzheimer’s Dis.* **76**, 1103–1120
929 (2020).
- 930 32. Claassen, J. A. H. R., Thijssen, D. H. J., Panerai, R. B. & Faraci, F. M. Regulation
931 of cerebral blood flow in humans: physiology and clinical implications of
932 autoregulation. *Physiol. Rev.* **101**, 1487–1559 (2021).
- 933 33. Schaeffer, S. & Iadecola, C. Revisiting the neurovascular unit. *Nat. Neurosci.* **24**,
934 1198–1209 (2021).
- 935 34. Smeijer, D., Ikram, M. K. & Hilal, S. Enlarged Perivascular Spaces and Dementia:
936 A Systematic Review. *J. Alzheimers. Dis.* **72**, 247–256 (2019).
- 937 35. Rensma, S. P., van Sloten, T. T., Launer, L. J. & Stehouwer, C. D. A. Cerebral
938 small vessel disease and risk of incident stroke, dementia and depression, and

- 939 all-cause mortality: A systematic review and meta-analysis. *Neurosci. Biobehav.*
940 *Rev.* **90**, 164–173 (2018).
- 941 36. Zhu, Y.-C. *et al.* High Degree of Dilated Virchow-Robin Spaces on MRI is
942 Associated with Increased Risk of Dementia. *J. Alzheimer's Dis.* **22**, 663–672
943 (2010).
- 944 37. Romero, J. R. *et al.* MRI-Visible Perivascular Spaces and Risk of Incident
945 Dementia. *Neurology* **99**, e2561–e2571 (2022).
- 946 38. Xiong, L. *et al.* Dementia incidence and predictors in cerebral amyloid angiopathy
947 patients without intracerebral hemorrhage. *J. Cereb. Blood Flow Metab.* **38**, 241–
948 249 (2018).
- 949 39. Ding, J. *et al.* Large Perivascular Spaces Visible on Magnetic Resonance
950 Imaging, Cerebral Small Vessel Disease Progression, and Risk of Dementia.
951 *JAMA Neurol.* **74**, 1105 (2017).
- 952 40. Bouvy, W. H. *et al.* Visualization of Perivascular Spaces and Perforating Arteries
953 With 7 T Magnetic Resonance Imaging. *Invest. Radiol.* **49**, 307–313 (2014).
- 954 41. Jochems, A. C. C. *et al.* Relationship Between Venules and Perivascular Spaces
955 in Sporadic Small Vessel Diseases. *Stroke* **51**, 1503–1506 (2020).
- 956 42. George, I. C. *et al.* A Novel Method to Measure Venular Perivascular Spaces in
957 Patients with MS on 7T MRI. *Am. J. Neuroradiol.* **42**, 1069–1072 (2021).
- 958 43. Weiner, M. W. *et al.* *The Alzheimer's Disease Neuroimaging Initiative 3:*
959 *Continued innovation for clinical trial improvement. Alzheimer's and Dementia* **13**,
960 561–571 (Elsevier Inc., 2017).

- 961 44. Beekly, D. L. *et al.* The National Alzheimer's Coordinating Center (NACC)
962 database: The uniform data set. *Alzheimer Dis. Assoc. Disord.* **21**, 249–258
963 (2007).
- 964 45. LaMontagne, P. J. *et al.* OASIS-3: Longitudinal Neuroimaging, Clinical, and
965 Cognitive Dataset for Normal Aging and Alzheimer Disease. *medRxiv*
966 2019.12.13.19014902 (2019). doi:10.1101/2019.12.13.19014902
- 967 46. Petersen, R. C. *et al.* Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical
968 characterization. *Neurology* **74**, 201 (2010).
- 969 47. Hachinski, V. C. *et al.* Cerebral Blood Flow in Dementia. *Arch. Neurol.* **32**, 632–
970 637 (1975).
- 971 48. Yesavage, J. A. *et al.* Development and validation of a geriatric depression
972 screening scale: a preliminary report. *J. Psychiatr. Res.* **17**, 37–49 (1982).
- 973 49. Budelier, M. M. & Bateman, R. J. Biomarkers of Alzheimer Disease. *J. Appl. Lab.*
974 *Med.* **5**, 194 (2020).
- 975 50. Landau, S. M. *et al.* Amyloid deposition, hypometabolism, and longitudinal
976 cognitive decline. *Ann. Neurol.* **72**, 578–586 (2012).
- 977 51. Royse, S. K. *et al.* Validation of amyloid PET positivity thresholds in centiloids: a
978 multisite PET study approach. *Alzheimer's Res. Ther.* **13**, 1–10 (2021).
- 979 52. Jagust, W. J. *et al.* The ADNI PET Core. *Alzheimers. Dement.* **6**, 221 (2010).
- 980 53. Fagan, A. M. *et al.* Comparison of analytical platforms for cerebrospinal fluid
981 measures of A β 1-42, total tau and p-tau181 for identifying Alzheimer's disease
982 amyloid plaque pathology. *Arch. Neurol.* **68**, 1137 (2011).

- 983 54. Shaw, L. M. *et al.* Cerebrospinal Fluid Biomarker Signature in Alzheimer’s
984 Disease Neuroimaging Initiative Subjects. *Ann. Neurol.* **65**, 403 (2009).
- 985 55. Morris, J. C. The Clinical Dementia Rating (CDR). *Neurology* **43**, 2412.2-2412-a
986 (1993).
- 987 56. Folstein, M. F., Folstein, S. E. & McHugh, P. R. ‘Mini-mental state’. A practical
988 method for grading the cognitive state of patients for the clinician. *J. Psychiatr.*
989 *Res.* **12**, 189–198 (1975).
- 990 57. Fischl, B. FreeSurfer. *Neuroimage* **62**, 774–781 (2012).
- 991 58. Reuter, M., Schmansky, N. J., Rosas, H. D. & Fischl, B. Within-Subject Template
992 Estimation for Unbiased Longitudinal Image Analysis. *Neuroimage* **61**, 1402–1418
993 (2012).
- 994 59. Barisano, G. *et al.* The effect of prolonged spaceflight on cerebrospinal fluid and
995 perivascular spaces of astronauts and cosmonauts. *Proc. Natl. Acad. Sci.* **119**,
996 e2120439119 (2022).
- 997 60. Wilcock, D. *et al.* MarkVCID cerebral small vessel consortium: I. Enrollment,
998 clinical, fluid protocols. *Alzheimers. Dement.* **17**, 704–715 (2021).
- 999 61. Somerville, L. H. *et al.* The Lifespan Human Connectome Project in Development:
1000 A large-scale study of brain connectivity development in 5–21 year olds.
1001 *Neuroimage* **183**, 456–468 (2018).
- 1002 62. Bookheimer, S. Y. *et al.* The Lifespan Human Connectome Project in Aging: An
1003 overview. *Neuroimage* **185**, 335–348 (2019).
- 1004 63. Van Essen, D. C. *et al.* The WU-Minn Human Connectome Project: An overview.

- 1005 *Neuroimage* **80**, 62–79 (2013).
- 1006 64. Schoenfeld, D. Partial residuals for the proportional hazards regression model.
1007 *Biometrika* **69**, 239–241 (1982).
- 1008 65. Durrleman, S. & Simon, R. Flexible regression models with cubic splines. *Stat.*
1009 *Med.* **8**, 551–561 (1989).
- 1010 66. Holm, S. A Simple Sequentially Rejective Multiple Test Procedure. *Scand. J. Stat.*
1011 **6**, 65–70 (1979).
- 1012 67. Therneau, T. M. & Grambsch, P. M. *Modeling Survival Data: Extending the Cox*
1013 *Model*. (Springer New York, 2000). doi:10.1007/978-1-4757-3294-8
- 1014 68. Schwarzer, G., Carpenter, J. R. & Rücker, G. *Meta-Analysis with R*. (Springer
1015 International Publishing, 2015). doi:10.1007/978-3-319-21416-0
- 1016 69. Bates, D., Mächler, M., Bolker, B. M. & Walker, S. C. Fitting Linear Mixed-Effects
1017 Models Using lme4. *J. Stat. Softw.* **67**, 1–48 (2015).
- 1018 70. Lüdtke, D. ggeffects: Tidy Data Frames of Marginal Effects from Regression
1019 Models. *J. Open Source Softw.* **3**, 772 (2018).
- 1020 71. Iddi, S. & C Donohue, M. Power and Sample Size for Longitudinal Models in R --
1021 The longpower Package and Shiny App. *R J.* **14**, 264–282 (2022).
- 1022 72. Mowinckel, A. M. & Vidal-Piñeiro, D. Visualization of Brain Statistics With R
1023 Packages ggseg and ggseg3d. *Adv. Methods Pract. Psychol. Sci.*
1024 251524592092800 (2020). doi:10.1177/2515245920928009
- 1025 73. Wickham, H. *ggplot2*. (Springer International Publishing, 2016). doi:10.1007/978-

1026 3-319-24277-4

1027

1028